KFI
KPTI icon

Key Financial Inc’s Karyopharm Therapeutics KPTI Stock Holding History

Key Financial Inc’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10
Closed -$819 – 1192
2022
Q4 		$819 Hold
10
– – ﹤0.01% 1055
2022
Q3 		$1K Buy
+10
New +$747 ﹤0.01% 1049

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Key Financial Inc's KPTI Position: Q1 2023 in Review

Key Financial Inc sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 10 shares — an estimated $819 sold.

Key Financial Inc first reported a position in KPTI in Q3 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

  • Key Financial Inc reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Key Financial Inc sold 10 Karyopharm Therapeutics shares in Q1 2023, an estimated $819.
  • Key Financial Inc first reported a position in Karyopharm Therapeutics in Q3 2022 and held it in 2 quarters.
  • Key Financial Inc's Karyopharm Therapeutics position peaked at $1K in Q3 2022.
  • 129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Key Financial Inc's 13F filing for Q1 2023, filed 2 May 2023.